Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday Dec. 7, 2009

DrStockPick.com Stock Report!

PWRM, CTIC, CELG

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro(R)) and breast cancer (BC-SeraPro(TM)). PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.

PWRM reported that the company’s President and CSO, Dr. Ira Goldknopf, delivered an invited Keynote address and chaired a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting was “New Leadership of Personalized Medicine.”

Dr. Goldknopf described the company’s unique ability to employ PWRM’s blood protein biomarkers to differentially diagnose mild Alzheimer’s and Parkinson’s diseases, distinguish between them, distinguish from normal controls, distinguish from patients with Alzheimer’s and Parkinson’s like disorders (disease controls) and distinguish drug naive and drug treated patients. He also presented results for early diagnosis of invasive breast cancer with and without ductal carcinoma in situ, distinguishing between them, distinguishing them from normal and benign controls. The final topic covered was the discovery of biomarkers in bone marrow cells from chronic myelogenous leukemia patients that predict whether they would respond to the drug imatinib mesylate (Gleevec).

More about PWRM at www.power3medical.com

**************************************************************

CTIC, Cell Therapeutics, Inc.

CTIC is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

CTIC announced today that Ruth Pettengell, M.D. of St. George’s Hospital, University of London during a session at the 2009 American Society of Hematology (”ASH”) Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the “PIX 301 EXTEND trial”) in relapsed or refractory, aggressive non-Hodgkin’s lymphoma (”NHL”) patients who have failed 2 or more prior therapies. Updated analyses with additional follow-up data were conducted; these analyses and additional follow-up data support the initial clinical trial results. Subgroup analyses examining the effect of age, IPI score, disease status, or prior anthracycline doses on Progression Free Survival (PFS) demonstrated that pixantrone consistently improved PFS across subgroups compared with other chemotherapy agents. With patients in follow-up period at least 9 months from end of treatment, pixantrone provided a 250% relative improvement in 1 year PFS (21% Vs 6%) over comparator and a 115% increase in median overall PFS (5.6 months Vs 2.6 months, p=0.002, HR =0.56). The benefit on PFS was independent of risk factors. At 21 months, 14% of pixantrone patients remained free from disease progression versus 3% in the comparator arm.

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer.

More about CTIC at www.CellTherapeutics.com.

**************************************************************

CELG, Celgene Corporation

CELG is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

CELG and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement under which CELG will acquire Gloucester Pharmaceuticals. CELG says the acquisition will continue to advance its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Gloucester Pharmaceuticals develops new therapies that address the unmet medical needs in the treatment of cancer, including cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) and other hematological malignancies.

More about CELG at www.celgene.com.

**************************************************************

Keep a close eye on PWRM, CTIC and CELG, do your homework, and like always BE READY for the ACTION!

***********Advertisement***********

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.

Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and it has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

_______________________________________________________

_______________________________________________________

Dr. Stock Pick is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1400 websites www.crwenews.com, www.stock-ir.com, www.PennyOmega.com, www.BestOTC.com, www.stock-pr.com giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com

email: investor@drstockpick.com

Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com